The MCL1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, designed to disrupt the anti-apoptotic gene MCL1. This polyclonal knockout model provides a heterogeneous pool of edited cells, enabling functional studies of MCL1 loss without selection for a single clonal genotype. The gene disruption is achieved through CRISPR/Cas9-mediated targeting, resulting in a mixed population that can be used directly in pooled functional assays or further enriched by selection strategies, offering a robust system for investigating MCL1-dependent phenotypes in a lymphoblastoid background.
Raji cells, derived from an 11-year-old male with Burkitt lymphoma, serve as a well-characterized lymphoblastoid B cell line widely used in immunological and cancer research. These suspension cells exhibit typical B lymphocyte markers and have been instrumental in studying B cell biology, oncogenic signaling, and apoptosis regulation. Their rapid proliferation and established role as a model for hematologic malignancies make them an ideal host for evaluating the impact of anti-apoptotic protein disruption. The Raji background is particularly relevant for exploring MCL1 biology, given the frequent overexpression of MCL1 in Burkitt lymphoma and related lymphoid cancers.
MCL1 encodes an anti-apoptotic member of the BCL-2 family, which normally sequesters pro-apoptotic effectors BAK and BAX to prevent mitochondrial outer membrane permeabilization and subsequent cytochrome c release. MCL1 is regulated by multiple upstream signaling pathways, including IL-6 via JAK/STAT3 activation, PI3K/AKT/mTOR axis, and MAPK/ERK signaling, which promote its expression and stability. Its protein stability is also modulated by interacting factors such as USP9X (deubiquitinase) and MULE/SCF ubiquitin ligases. Knockout of MCL1 ablates this protective function, deepressing BAK and BAX, facilitating their oligomerization, and triggering apoptosome formation with downstream caspase-9 and caspase-3 activation, thereby sensitizing cells to intrinsic apoptosis.
In the Raji cell context, MCL1 knockout is particularly significant for dissecting survival mechanisms in B cell malignancies. Raji cells rely on anti-apoptotic signals to sustain their transformed phenotype, and MCL1 is often a critical factor in chemoresistance and disease progression. Disruption of MCL1 in this polyclonal population allows researchers to examine the direct consequences on viability, apoptosis induction, and clonal fitness without the confounding effects of clonal selection. This model can be used to probe MCL1 dependency in the presence of upstream stimuli like IL-6 or growth factors, and to assess how the PI3K/AKT and MAPK/ERK pathways converge on MCL1-mediated survival.
This knockout polyclonal cell product is designed for a range of applications, including the study of intrinsic apoptosis mechanisms, drug resistance profiling, and functional genomic screening for MCL1-dependent vulnerabilities. Researchers can employ western blotting to confirm MCL1 loss and monitor apoptotic markers, flow cytometry with Annexin V/PI to quantify apoptosis, cell viability assays (MTT or CellTiter-Glo) to assess survival, co-immunoprecipitation to analyze BAK/BAX release from MCL1 complexes, and RNA-seq to capture transcriptional adaptation. The polyclonal nature supports pooled screens and pharmacodynamic studies where heterogeneous responses reflect therapeutic potential. For further information, please contact Ascent Research.
